Presentation Unknown Attendee So our final panel of the day is about vaccines. Everyone, if we could please quiet down, if you don't mind. Thank you. So our final panel today is on vaccine access and development. I'm joined here by my colleague, research analyst, Elena Meng from Gabelli Funds; Michelle Kehily, VP U.S. Pediatric and Pipeline Vaccines at Merck; Dr. Stephen Morse, Professor of Epidemiology at Columbia Mailman School of Public Health; Michael Paas, VP, Head of Value & Access at AbbVie; and fi ...

 Vancouver, Canada – November 14, 2025 – TheNewswire – URZ3 Energy Corp. (“URZ” or the “Company”) (TSX-V: URZ; OTCQB: NVDEF) announces it has extended the Alphai News Corp. (“Alphai”) agreement (see news release dated December 16, 2024) to provide comprehensive digital media and capital markets communications services. This collaboration aims to enhance the Company’s online visibility and strengthen engagement with potential investors and shareholders.Under the extension, Alphai will assist the Company wit ...

November 14, 2025 – TheNewswire - Nord Precious Metals Mining Inc. (TSX-V: NTH | OTCQB: CCWOF | FRANKFURT: QN3) (“Nord” or the “Company”) announces its prior engagements of four consultants to conduct investor relations services and/or promotional activities, as such activities are defined under the policies of the TSX Venture Exchange (“TSXV”) and applicable securities laws. The Company entered into a service contract with Departure Capital Inc. (“Departure”) effective April 8, 2025, for an initial six-mo ...

Summary of Merck & Co (NYSE:MRK) FY Conference - November 14, 2025 Industry Overview - The discussion focused on the vaccine industry, particularly vaccine access, development, and public trust in vaccination [2][18][22]. Key Points and Arguments Vaccine Hesitancy and Public Trust - Vaccine hesitancy has increased from approximately 5% to 10% among parents over the last five years, although the majority still choose vaccination for their children [3][4]. - Trust in healthcare professionals remains high, with pediatricians being the most trusted source of information for parents [4][5]. - Broader societal and political divides contribute to vaccine hesitancy, particularly regarding seasonal vaccinations like COVID-19 [4][12]. Value and Access in Vaccination - The value and access functions in the pharmaceutical industry focus on demonstrating the value of vaccines and ensuring patient access [6][7]. - Effective communication with healthcare decision-makers is crucial, emphasizing the broader societal benefits of vaccines, such as productivity gains and educational attainment [9][10]. - A dollar invested in vaccines can yield a return of $20 to $50, highlighting the economic value of vaccination [10]. Global Vaccine Access and Innovation - The Vaccines for Children Program provides zero-cost coverage for 50% of American children, indicating good access to pediatric vaccines [19][20]. - In a constrained pricing environment, maintaining incentives for innovation while ensuring vaccine accessibility is a challenge [22][23]. - Creative solutions, such as public-private partnerships and advanced market commitments, can help balance pricing and access [24][25]. Surveillance and Equity in Vaccine Distribution - Improved global surveillance can enhance equitable vaccine manufacturing and distribution, as seen in historical examples like smallpox eradication [28][30]. - Regionalizing vaccine manufacturing could address equity issues and improve response times during outbreaks [30]. Practical Barriers to Vaccine Implementation - Clinicians face practical barriers such as time constraints during patient visits, which can hinder discussions about vaccination [33][34]. - Workflow considerations, including vaccine storage and availability, are critical for successful vaccine implementation [34][35]. Future Directions in Vaccine Development - New understandings of immune tolerance and regulatory T cells could shape the next generation of vaccines [36][37]. - The importance of investing in surveillance, basic science research, and clinical trial infrastructure is emphasized for pandemic preparedness [44][46]. Communication of Vaccine Value - Communicating the broader societal and economic value of vaccines to payers and policymakers is essential for gaining support [38][39]. - A holistic approach to defining vaccine value, beyond just cost, is necessary to engage various stakeholders effectively [38][39]. Anticipatory R&D and Vaccine Platforms - There is a need for anticipatory R&D pipelines to prepare for future pandemics and neglected diseases, focusing on surveillance and environmental monitoring [44][46]. - The potential for developing vaccines that target multiple pathogens could revolutionize preventive healthcare [45][70]. Other Important Insights - The role of trusted local voices, such as pediatricians and community leaders, is crucial in translating vaccine policies into actionable information for parents [50][51]. - The integration of AI in vaccine development and public health messaging could enhance understanding and trust in vaccination [60][63]. This summary encapsulates the critical discussions and insights from the Merck & Co FY Conference, highlighting the complexities and opportunities within the vaccine industry.

Summary of Vaccine Access and Development Panel Discussion Industry Focus - **Industry**: Vaccine Development and Public Health Key Points and Arguments Vaccine Hesitancy and Public Trust - Vaccine hesitancy has increased from approximately 5% to 10% among parents over the last five years, although the majority still choose vaccination for their children [3][4] - Trust in healthcare professionals remains high, with pediatricians being the most trusted source of information for parents [4][5] - Broader societal and political divides contribute to vaccine hesitancy, particularly regarding seasonal vaccinations like COVID-19 [2][4] Value and Access in Vaccination - The value and access functions in the pharmaceutical industry focus on demonstrating the value of vaccines and ensuring patient access [6][7] - Effective communication with healthcare decision-makers is crucial, emphasizing the broader societal benefits of vaccines, such as productivity gains and educational attainment [9][10] - A dollar invested in vaccines can yield a return of $20 to $50, highlighting the economic value of vaccination [10] Barriers to Vaccine Access - Access to vaccines is generally good in the pediatric space, with programs like Vaccines for Children covering 50% of American children [19][20] - However, access to information and healthcare remains a challenge, leading to pockets of under-vaccinated children [20] Global Vaccine Economics - The economics of biopharmaceuticals are complex, with high costs and risks associated with bringing vaccines to market [21][22] - Innovative partnerships and pricing strategies are necessary to maintain incentives for vaccine development while ensuring accessibility [23][24] Importance of Surveillance - Improved global surveillance can enhance equitable vaccine manufacturing and distribution, as seen in the eradication of smallpox [26][29] - Surveillance can help identify outbreaks and inform targeted vaccination efforts [29] Practical Barriers in Clinical Settings - Time constraints during patient visits can hinder discussions about vaccination, impacting implementation [32][33] - Workflow considerations, such as vaccine storage and availability, are critical for successful vaccination programs [33] Future Directions in Vaccine Development - Advances in understanding immune tolerance and regulatory T cells may shape the next generation of vaccines [34][35] - The potential for AI to analyze vast amounts of data could enhance vaccine development and public health messaging [62][63] Anticipatory R&D for Pandemic Preparedness - Investment in disease surveillance and basic science research is essential for anticipating future health threats [42][43] - The development of vaccines that can target multiple pathogens is a promising area for future research [45] Conclusion - The panel emphasized the need for collaboration among stakeholders, effective communication, and innovative strategies to enhance vaccine access and public trust in vaccination efforts [50][68]

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Friday.The Dow traded down 0.44% to 47,249.55 while the NASDAQ rose 0.59% to 23,004.91. The S&P 500 also rose, gaining, 0.27% to 6,755.73.Check This Out: Top 2 Financial Stocks That May Plunge This QuarterLeading and Lagging SectorsUtilities shares rose by 0.1% on Friday.In trading on Friday, communication services stocks fell by 1%.Top HeadlineShares of Spire Inc (NYSE:SR) fell more than 2% on Friday afte ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Accessibility StatementSkip Navigation We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi & Fruchter LLP Guri AdemiToll Free: (866) 264-3995Fax: (414) 482-8001 SOURCE Ademi LLP 21% MILWAUKEE, Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Cidara (Nasdaq: CDTX) for possible breaches of fiduciary duty and oth ...

Key Takeaways Lilly's obesity portfolio features late-stage candidates orforglipron and retatrutide.Orforglipron, a daily oral GLP-1 pill, could offer a convenient option versus injectables.Retatrutide may enable deeper and faster weight loss, with key phase III data due from 2025-2027.Eli Lilly and Company (LLY) is one of the two companies that dominate the booming diabetes and obesity space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the ...

Group 1: Nvidia - Nvidia is experiencing a mix of pressure and positive sentiment, with analysts expressing confidence in its future performance [1][2] - Wells Fargo raised its price target for Nvidia to $265, anticipating Q3 sales between $50 billion and $52 billion, driven by growing AI demand [2][3] - Morgan Stanley also increased its price target to $220, labeling Nvidia as a core winner in the ongoing AI buildout [3] - Dan Ives from Wed Bush views the current tech pullback as a buying opportunity, asserting that Nvidia is foundational to the AI revolution and expects growth to continue into 2026 [4][5] Group 2: StubHub - StubHub's stock dropped over 20% following disappointing quarterly results and the lack of guidance for the upcoming quarter [6][7] - The company reported a loss exceeding $1.3 billion, with a loss per share of $427, significantly up from $45.9 million the previous year [7][8] - StubHub attributed its losses to a $1.4 billion stock-based compensation charge related to its IPO, but investors reacted negatively [7][8][9] Group 3: Merck - Merck announced a $9.2 billion acquisition of Sedara Therapeutics, leading to a more than 100% increase in Sedara's shares [10][11] - The acquisition aims to provide access to an experimental flu prevention drug, which could serve as a universal protection against various flu strains [10][12] - This move is part of Merck's strategy to diversify its portfolio ahead of the patent expiration of its blockbuster drug, Keytruda [12][13]